期刊文献+

Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis 被引量:18

Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis
下载PDF
导出
摘要 AIM: To investigate the relationship between transcatheterarterial embolization (TAE) and pulmonary metastasis insubjects with hepatocellular carcinoma (HCC). METHODS: A total of 287 patients with HCC followed upfor more than 1 week were included. 102 patients underwenttranscatheter arterial embolization (TAE group) and 185received conservative treatment(control group). Thepatients' chest x-rays and chest CT scans were examinedfor pulmonary metastasis.RESULTS: Patients with TAE had a median survival of 19.3months while that of the control group was only 10.0 months(P<0.05). Pulmonary metastasis occurred in 14 (13.7 %)patients in the TAE group and 14 (7.6 %) patients in the control group, there was no significant difference (P>0.05).The 1-year, 2-year and 5-year cumulative incidence of pulmonary metastasis was 11.8 %, 17.6 % and 24.0 % in the TAE group and 7.0 %, 13.0 % and 21.7 % in the control group, respectively (P>0.05). On the univariate analysis,tumor size, abnormal serum alanine aminotransferase levels and heterogeneity on sonography were significantly associated with pulmonary metastasis. However, on the multivariate analysis, only tumor size was significantly predictive of pulmonary metastasis.CONCLUSION: TAE is effective on prolonging survival of patients with HCC. It does not significantly increase the risk of pulmonary metastasis. Tumor size is the only significant predictive factor associated with lung metastasis. AIM:To investigate the relationship between transcatheter arterial embolization (TAE) and pulmonary metastasis in subjects with hepatocellular carcinoma (HCC). METHODS:A total of 287 patients with HCC followed up for more than 1 week were included.102 patients underwent transcatheter arterial embolization (TAE group) and 185 received conservative treatment (control group).The patients' chest x-rays and chest CT scans were examined for pulmonary metastasis. RESULTS:Patients with TAE had a median survival of 19.3 months while that of the control group was only 10.0 months (P<0.05).Pulmonary metastasis occurred in 14 (13.7 %) patients in the TAE group and 14 (7.6 %) patients in the control group,there was no significant difference (P>0.05). The 1-year,2-year and 5-year cumulative incidence of pulmonary metastasis was 11.8 %,17.6 % and 24.0 % in the TAE group and 7.0 %,13.0 % and 21.7 % in the control group,respectively (P>0.05).On the univariate analysis, tumor size,abnormal serum alanine aminotransferase levels and heterogeneity on sonography were significantly associated with pulmonary metastasis.However,on the multivariate analysis,only tumor size was significantly predictive of pulmonary metastasis. CONCLUSION:TAE is effective on prolonging survival of patients with HCC.It does not significantly increase the risk of pulmonary metastasis.Tumor size is the only significant predictive factor associated with lung metastasis.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2003年第6期1208-1211,共4页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献26

  • 1Beasley RIP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2:1129-1133.
  • 2Rustgi V. Epidemiology of hepatoceUular cancer. Ann Intern Med 1988; 108:390-397.
  • 3Curley SA, Levin B, Rich TA. Liver and bile ducts. In: Abeloff MD, Armitage JO, Lichter AS. eds. Clinical Oncology. New York:Churchill Livingstone, Inc, 1995:1305-1372.
  • 4Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, Kimoto T, Takemoto Y, Nakamura T, Yukaya H. Liver resection for hepatoceUular carcinoma: results of 229 consecutive patients during 11 years. Ann Surg 1993; 217:375-384.
  • 5Curley SA,Izzo F, Ellis LM,-Nicolas Vauthey J, Vallone P.Radiofrequency ablation of hepatoceUular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232:381-391.
  • 6Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A,Rapaccini GL, Salmi A, Torzilli G. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis.Cancer 1992; 69:925-929.
  • 7Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference: hepatoceUular carcinoma. Ann Intern Med 1988; 108:390-401.
  • 8Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N,Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment:, study of 850 patients. Cancer 1985; 56:918-928.
  • 9Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K,Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397-401.
  • 10Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I,Zavaglia C, Alberti A, Ideo G. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors.Hepatology 1994; 19:1115-1123.

同被引文献119

引证文献18

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部